100,000 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Acquired by Integral Health Asset Management LLC

Integral Health Asset Management LLC purchased a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 100,000 shares of the company's stock, valued at approximately $1,742,000. Integral Health Asset Management LLC owned 0.13% of Travere Therapeutics as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Sterling Capital Management LLC grew its position in Travere Therapeutics by 859.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after purchasing an additional 2,115 shares during the period. R Squared Ltd purchased a new stake in Travere Therapeutics during the fourth quarter valued at $53,000. Gen Wealth Partners Inc purchased a new stake in Travere Therapeutics during the fourth quarter valued at $73,000. Summit Investment Advisors Inc. increased its position in Travere Therapeutics by 9.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock valued at $138,000 after acquiring an additional 667 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Travere Therapeutics during the fourth quarter valued at $182,000.

Travere Therapeutics Price Performance

NASDAQ TVTX traded down $4.35 during trading on Friday, hitting $16.80. 5,965,164 shares of the stock traded hands, compared to its average volume of 1,562,237. Travere Therapeutics, Inc. has a 12-month low of $6.01 and a 12-month high of $25.29. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The firm has a 50-day simple moving average of $18.25 and a 200-day simple moving average of $18.91. The company has a market capitalization of $1.49 billion, a P/E ratio of -4.10 and a beta of 0.88.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. During the same period in the prior year, the business earned ($1.76) EPS. The business's revenue for the quarter was up 83.3% compared to the same quarter last year. As a group, analysts predict that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Insider Activity

In other Travere Therapeutics news, CEO Eric M. Dube sold 18,924 shares of the stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the sale, the chief executive officer now directly owns 419,173 shares in the company, valued at approximately $8,823,591.65. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Peter Heerma sold 1,771 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,279.55. Following the completion of the transaction, the insider now directly owns 128,215 shares in the company, valued at $2,698,925.75. This represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,527 shares of company stock worth $473,814. Corporate insiders own 4.19% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. JPMorgan Chase & Co. upped their price target on Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Cantor Fitzgerald restated an "overweight" rating on shares of Travere Therapeutics in a research report on Wednesday, April 23rd. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Stifel Nicolaus raised their price objective on shares of Travere Therapeutics from $22.00 to $23.00 and gave the company a "hold" rating in a research report on Friday, May 2nd. Finally, Citigroup raised their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.79.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.